Effects of (5Z)-7-oxozeaenol on MDA-MB-231 breast cancer cells

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2415-2421

  Muñoz Acuña, Ulyana ^a   Wittwer, Jennifer ^a   Ayers, Sloan ^b   Pearce, Cedric J ^c   Oberlies, Nicholas H ^b   Carcache De Blanco, Esperanza J ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

^c Mycosynthetix Inc   (United States)

Author keywords

(5Z) 7 oxozeaenol; Apoptosis; Caspase 7; IKK; MDA MB 231; NF B; ROS

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 7 OXOZEAENOL; ANTINEOPLASTIC AGENT; CASPASE 7; HYDROGEN PEROXIDE; I KAPPA B ALPHA; I KAPPA B BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PACLITAXEL; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL ADHESION; CELL CYCLE G1 PHASE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CHEMICAL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL ADHESION; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; ESTROGENS, NON-STEROIDAL; FEMALE; FLOW CYTOMETRY; HUMANS; NF-KAPPA B; REACTIVE OXYGEN SPECIES; ZEARALENONE;

EID: 84865675642     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Mur C, Martinez-Carpio PA, Fernandez-Montoli ME, Ramon JM, Rosel P and Navarro M A: Growth of MDA-MB-231 cell line: different effects of TGF-beta(1), EGF and estradiol depending on the length of exposure. Cell Biol Int 22: 679-684, 1998. (Pubitemid 29370942)
2. Hui L, Zheng Y, Yan Y, Bargonetti J and Foster DA: Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. Oncogene 25: 7305-7310. 2006. (Pubitemid 44809096)
3. Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME and Collins-Burow B M: Targeting triple-negative breast cancer cells with the HDAC inhibitor Panobinostat. Breast Cancer Res 14: R79, 2012.
4. Lerebours F, Vacher S, Andrieu C, Espie M, Marty M, Lidereau R and Bieche I: NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer 8: 41. 2008.
5. Muñoz Acuña U, Wittwer J, Ayer S, Pearce C, Oberlies N.H and Carcache de Blanco EJ: Effects of (5Z)-7-Oxozeaenol on the oxidative pathway of cancer cells. Anticancer Res 32, 2012.
6. Ninomiya-Tsuji J, Kajino T, Ono K, Ohtomo T, Matsumoto M, Shiina M, Mihara M, Tsuchiya M and Matsumoto K: A resorcylic acid lactone, (5Z)-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J Biol Chem 278: 18485-18490, 2003. (Pubitemid 36799472)
7. Eisen A, Akerele C, Reyderman L, Verbel DA, Simon JS, Davis, DW, Nomoto K and Wang J: CTC biomarker assessment to aid dosing selection of E6201, a potential MEK1 inhibitor, for treatment of BRAF-mutated melanoma. Ann Oncol 21: 405-405, 2010.
8. Shen Y, Boivin R, Yoneda N, Du H, Schiller S, Matsushima T, Goto M, Shirota H, Gusovsky F, Lemelin C, Jiang Y, Zhang Z, Pelletier R, Ikemori-Kawada M, Kawakami Y, Inoue A, Schnaderbeck M and Wang Y: Discovery of anti-inflammatory clinical candidate E6201, inspired from resorcylic lactone LL-Z1640-2, III. Bioorg Med Chem Lett 20 : 3155-3157, 2010.
9. Muramoto K, Goto M, Inoue Y, Ishii N, Chiba K, Kuboi Y, Omae T, Wang YJ, Gusovsky F and Shirota H: E6201, a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1 and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase-1: in vivo effects on cutaneous inflammatory responses by topical administration. J Pharmacol Exp Ther 335: 23-31, 2010.
10. Ayers S, Graf T N, Adcock AF, Kroll DJ, Matthew S, Carcache de Blanco EJ, Shen Q, Swanson SM, Wani MC, Pearce CJ and Oberlies NH. Resorcylic acid lactones with cytotoxic and NF-kappaB inhibitory activities and their structure-activity relationships. J Nat Prod 74: 1126-1131, 2011.
11. Kim JA, Lau EK, Pan L and Carcache de Blanco EJ: NF-kappaB inhibitors from Brucea javanica exhibiting intracellular effects on reactive oxygen species. Anticancer Res 30: 3295-3300, 2010.
12. Darnell JE: Transcription factors as targets for cancer therapy. Nat Rev Cancer 2: 740-749, 2002.
13. Yin Y, Chen X and Shu Y, Gene expression of the invasive phenotype of TNF-alpha-treated MCF-7 cells. Biomed Pharmacother 63: 421-428, 2009.
14. Perkins ND: Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8: 49-62, 2007.
15. Goto M, Chow J, Muramoto K, Chiba K, Yamamoto S, Fujita M, Obaishi H, Tai K, Mizui Y, Tanaka I, Young D, Yang H, Wang YJ, Shirota H and Gusovsky F: E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8, 9,16-trihydroxy-3,4-dimethyl-3,4,9,19- tetrahydro-1H-2-benzoxacyclotetradec ine-1,7(8H)-dione], a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1 and MEK kinase-1: in vitro characterization of its anti-inflammatory and antihyperproliferative activities. J Pharmacol Exp Ther 331: 485-495, 2009.
16. Takaesu G, Surabhi RM, Park KJ, Ninomiya-Tsuji J, Matsumoto K and Gaynor RB: TAK1 is critical for IkappaB kinase-mediated activation of the NF-kappaB pathway. J Mol Biol 326: 105-115, 2003. (Pubitemid 36279361)
17. Omori E, Morioka S, Matsumoto K and Ninomiya-Tsuji J: TAK1 regulates reactive oxygen species and cell death in keratinocytes, which is essential for skin integrity. J Biol Chem 283: 26161-26168, 2008.